Recruiting NCT03320304
This study is recruiting in the United Kingdom, in Belgium, in Austria, .... It is testing Effectiveness and Efficiency of VNS Therapy for depression.
Multiple locations, including Vienna Depression Behavioral Over 18 Years
Countries United Kingdom, Belgium, Austria, ...
Sponsor LivaNova
Condition Depression Recruiting NCT05511363
This study is recruiting in the United States, in France, in the United Kingdom, .... It is testing KarXT for Schizophrenia.
Multiple locations, including Homewood Schizophrenia Other From 55 Years to 90 Years
Countries United States, France, United Kingdom, ...
Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition Schizophrenia Recruiting NCT06126224
This study is recruiting in the United States, in Canada, in the United Kingdom, .... It is testing KarXT for Schizophrenia.
Multiple locations, including Chandler Schizophrenia Other From 55 Years to 90 Years
Countries United States, Canada, United Kingdom, ...
Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition Schizophrenia Recruiting NCT06540833
This study is recruiting in the United States, in Bulgaria, in Croatia, .... It is testing ITI-1284 for Schizophrenia.
Multiple locations, including Anaheim Schizophrenia Other Over 55 Years
Countries United States, Bulgaria, Croatia, ...
Sponsor Intra-Cellular Therapies, Inc.
Condition Schizophrenia Recruiting NCT06887192
This study is recruiting in the United States, in France, in Canada, .... It is testing ML-007C-MA for Schizophrenia.
Multiple locations, including Phoenix Schizophrenia Other From 55 Years to 90 Years
Countries United States, France, Canada, ...
Sponsor MapLight Therapeutics
Condition Schizophrenia Recruiting NCT06524830
This study is recruiting in the United States, in Australia, in Canada, .... It is testing VLS-01 Buccal Film, Compared to Placebo for treatment-resistant depression.
Multiple locations, including Tucson Depression Other From 18 Years to 65 Years
Countries United States, Australia, Canada, ...
Sponsor atai Therapeutics, Inc.
Condition Depression Recruiting NCT06929273
This study is recruiting in the United States, in Australia, in France, .... It is testing KarXT for manic episodes in bipolarity type I.
Multiple locations, including Glendale Bipolarity Drug i A study involving a medication or substance. From 18 Years to 65 Years
Countries United States, Australia, France, ...
Sponsor Bristol-Myers Squibb
Condition Bipolarity Recruiting ISRCTN15295182
This study is recruiting in Germany. It is testing digital intervention for depression.
In Germany Depression Other From 18 Years to 65 Years
Countries Germany
Sponsor Elona Health GmbH
Condition Depression Recruiting NCT06685965
This study is recruiting in Switzerland. It is testing Effects on Sleep and Safety of RE03 for PTSD.
In Zurich PTSD Drug From 18 Years to 64 Years
Countries Switzerland
Sponsor Reconnect Labs
Condition PTSD Recruiting NCT06585787
This study is recruiting in the United States, in France, in Belgium, .... It is testing KarXT for Schizophrenia.
Multiple locations, including Chandler Schizophrenia Other From 55 Years to 90 Years
Countries United States, France, Belgium, ...
Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition Schizophrenia Recruiting NCT07191483
This study is recruiting in the United States. It is testing KYN-5356 for schizophrenia.
Multiple locations, including Little Rock Schizophrenia Other From 18 Years to 55 Years
Countries United States
Sponsor Kynexis B.V.
Condition Schizophrenia Recruiting NCT06947941
This study is recruiting in the United States, in Australia, in Canada, .... It is testing Safety and Efficacy of KarXT + KarX-EC for Schizophrenia.
Multiple locations, including Gilbert Schizophrenia Other From 55 Years to 90 Years
Countries United States, Australia, Canada, ...
Sponsor Bristol-Myers Squibb
Condition Schizophrenia